Please login to the form below

Not currently logged in
Email:
Password:

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

It included women with either cervical squamous cell carcinoma or adenocarcinoma, who were randomised to receive Libtayo monotherapy or an investigator’s choice of commonly used chemotherapy. ... The NSCLC authorisation closely followed another

Latest news

  • Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

    This is the second approval for Libtayo this month, with the immunotherapy previously winning an authorisation in previously-treated advanced basal cell carcinoma. ... As a latecomer to the immunotherapy class, Libtayo first entered the market in 2018

  • Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

    cell carcinoma and cervical cancer. ... Sanofi and Regeneron aren’t holding back on the scale of their research programme, and these include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... metastatic non-small cell lung cancer (NSCLC),

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line

More from news
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The small-molecule drug blocks part of the Sonic hedgehog

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Curis looks to MedImmune and Takeda for new hires Curis looks to MedImmune and Takeda for new hires

    Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics